BioMed Research International / 2018 / Article / Tab 1

Research Article

CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders

Table 1

Clinical characteristics of patients with NMOSD and MS.

Clinical characteristics NMOSDMS
AQP4 Ab+

Sex ratio, F (%)24(96.0)3(37.5)11(68.8)9(75.0)
Age, years, mean (SD)44.7(17.0)38.3(8.5)42.1(11.4)37.4(16.0)
Disease duration, months, mean (SD)18.9(8.8)13.3(8.7)16.0(10.4)22.4(7.3)
Site of the lesions, n (%)
 Optic nerve15(60.0)3(37.5)7(43.6)3(25.0)
 Spinal cord25(100.0)6(75.0)14(87.5)7(58.3)
EDSS, median (range)6.5(2.0-8.5)4.3(3.5-7.0)6.3(2.5-8.0)3.5(2.0-5.0)
CSF analysis at attack
 CSF WBC count, mean (SD), /ul19.0(24.3)32.0(47.8)10.3(15.7)9.7(10.7)
 CSF protein level, mean (SD), mg/dl47.8(26.8)42.4(16.9)39.0(20.0)37.4(23.7)
 CSF IgG index, mean (SD)0.6(0.2)1.1(1.6)0.5(0.1)0.6(0.3)
 Positive oligoclonal bands, n (%)15(60.0)3(37.5)9(56.3)8(66.7)

Continuous variables are shown as the means (SD), and categorical variables are described as percentages. NMOSD, neuromyelitis optica spectrum disorder; AQP4 Ab+, aquaporin-4 antibody positive NMOSD; MOG-Ab+, myelin-oligodendrocyte glycoprotein antibody positive NMOSD; MS, multiple sclerosis; F, female; EDSS, Expanded Disability Status Scale; CSF, cerebrospinal fluid; WBC, white blood cell.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.